NANJING, China, July 14 Simcere Pharmaceutical Group(NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplierof branded generic and innovative pharmaceuticals in China, today announcedthat the annual general meeting of shareholders (the "Meeting") will be heldon Wednesday, July 28, 2010 at 10 a.m. Beijing time, at No.699-18, XuanwuAvenue, Xuanwu District, Nanjing, People's Republic of China.
All shareholders of record at the close of business on July 16, 2010 willbe entitled to attend and vote at the Meeting, and at any adjournment orpostponement thereof, or to appoint a proxy to attend and vote in his/herplace. The proxy need not be a shareholder of the Company.
This notice and other information with regards to the Meeting areavailable on the investor relation section of the Company's website:http://www.simcere.com .
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leadingpharmaceutical company specializing in the development, manufacturing, andmarketing of branded generic and proprietary pharmaceuticals in China. Inrecent years, Simcere has been focusing its strategy on the development ofinnovative pharmaceuticals and first-to-market generics, and has introduced aninnovative anti-cancer medication Endu, a first-to-market medication Sinofuan,and first-to-market generics such as Bicun and Anxin. Simcere manufactures andsells antibiotics, anti-cancer medication, stroke management medication andbiopharmaceutical drugs such as vaccines. Simcere concentrates its researchand development efforts on the treatment of diseases with high incidenceand/or mortality rates and for which there is a clear demand for moreeffective pharmacotherapy such as cancer, strokes, orthopaedics and infectiousdiseases. For more information about Simcere Pharmaceutical Group, pleasevisit http://www.simcere.com .The meeting is being held for the following purposes: 1. To receive a report on the Company's operation; 2. To transact any other business properly brought before the Meeting.
SOURCE Simcere Pharmaceutical Group